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Summary The relationship between DNA content of mammary cancer and subsequent response to endocrine
therapy was studied in 136 patients with advanced disease. All were treated with tamoxifen or ovarian
ablation as first-line systemic therapy after relapse and were evaluable for response according to UICC
criteria. DNA characterisation by flow cytometry was used on formalin fixed paraffin-embedded samples of
tumour. Tumours were grouped according to DNA index into diploid (n = 52, 38%), 'tetraploid' (n=46, 34%)
and 'other DNA-aneuploid' (n=38, 28%). The highest proportion of oestrogen receptor positive tumours
(ER+ve) was found in the 'tetraploid' tumours (38/46, 85%, Chi-square=8.53, P<0.02), and response rates,
(SD +PR+CR), were 26/52 (50%), 34/46 (74%), and 15/38 (39%) respectively (Chi-square= 10.88, P<0.005).
Patients with diploid or 'tetraploid' tumours survived longer and stayed in remission longer than those with
other DNA-aneuploid' tumours. We suggest that 'tetraploid' or 'near tetraploid' human mammary tumours
may comprise a distinct group of endocrine responsive tumours within the overall group of aneuploid
tumours. The conventional interpretation of DNA histograms, grouping into diploid and aneuploid, may be
masking important features of some tumour groups.
In the past cellular DNA ploidy was assessed by the use of
nucleic acid specific stains on tissue sections and microdensi-
tometry. Only relatively small numbers of cells could be
assessed. The development of flow cytometry (FCM) has
brought a rapid and reproducible technique for deter-
mination of DNA content of tumours. Thousands of nuclei
can be evaluated, and DNA histograms produced which
indicate different cell populations. The introduction of a
method whereby paraffin-embedded tumours may be used
for flow cytometric analysis has led to the examination of
archival material, and a means by which cellular DNA
content can be related to subsequent response to treatment,
survival and a variety of other factors (Hedley et al., 1983,
1985; Coon et al., 1986).
The manner in which studies have been reported con-
ventionally divided tumours into 'diploid' when the DNA
content of the cells is normal or near-normal, and
'aneuploid' when the content is clearly abnormal. Two thirds
(range 54-92%) of human mammary tumours have been
reported to be aneuploid (Olszewski et al., 1981a; Barlogie et
al., 1982; Raber et al., 1982; Cornelisse et al., 1984; Ewers et
al., 1984; Moran et al., 1984; Hedley et al., 1984, 1985;
McDivitt et al., 1986; Thorud et al., 1986; Horsfall et al.,
1986).
The results published so far are confusing. Findings
obtained with static cytometry suggest that patients with
diploid tumours survive longer than those with aneuploid
ones (Atkin et al., 1972; Auer et al., 1984), and a similar
trend has been found in one study with flow cytometry
(Coulson et al., 1984). One report indicates that aneuploid
tumours recur more rapidly than diploid tumours (Ewers et
al., 1984), but survival of patients after relapse is apparently
not related to DNA ploidy (Hedley et al., 1984; Stuart-
Harris et al., 1985). Aneuploidy has been associated with
lymph node metastases (Barlogie et al., 1982; Cornelisse et
al., 1984), but others have failed to confirm the relationship
(Taylor et al., 1983; Moran et al., 1984).
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There is a consistent trend for a greater proportion of
diploid tumours to be oestrogen receptor positive when
compared to aneuploid tumours; this difference achieves
statistical significance in some studies (Bichel et al., 1982;
Cornelisse et al., 1984; Coulson et al., 1984; Horsfall et al.,
1986) but not in others (Olszewski et al., 1981a; Raber et al.,
1982; Taylor et al., 1983; Hedley et al., 1984; McDivitt et al.,
1985; Kute et al., 1985).
In most series tetraploid tumours are included within the
total aneuploid group, but it is possible that not all
components of the total aneuploid group may behave in the
same way. In one study with static cytometry, longer
survival was found for patients with diploid or tetraploid
tumours when compared with the remainder, and this
suggests that further work is required to determine the
significance of some aneuploid subgroups (Auer et al., 1984).
In this study we have related receptor status, response to
endocrine therapy and survival from the start of endocrine
treatment to DNA content of tumour cells. Because of the
contradictory reports which result when tumours are
grouped only as either diploid or aneuploid, the analyses
were performed by DNA index, so that characteristics of
aneuploid sub-groups could be investigated separately
(Coulson et al., 1984; Hiddeman et al., 1984).
Patients and methods
Patients
This study was carried out on 136 patients who were treated
with endocrine therapy as first systemic treatment for
advanced mammary cancer, between 1975 and 1983, at the
University Hospital of South Manchester. They were chosen
because none had had any previous systemic treatment, all
were evaluable for response to endocrine manipulation
according to internationally accepted criteria (Hayward et
al., 1977), and all had had tumour steroid hormone receptors
measured.
Response was assessed as complete (CR) when all
measurable disease disappeared, partial (PR) when the size
of measurable lesions decreased >50% in at least two
planes, and static (SD) when the disease remained
unchanged for a minimum of 6 months. Non-responding
tumours were categorised as progressive disease (PD). SD
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was included with PR and CR as a positive response,
because patients with SD fared just as well as those with PR.
At the start of endocrine therapy 117 patients were post-
menopausal and were treated with tamoxifen 20mgday-1;
19 were premenopausal and treated by ovarian ablation. Forty
patients (29%), presented with locally advanced disease,
and 96 (71%) with recurrent disease after previous surgery:
they had a median disease free interval of 21 months.
Clinical characteristics of these 136 are shown (Table I).
Full blood count, serum biochemistry and radiography of
the chest, lumbar spine and pelvis were performed regu-
larly. Isotope bone scans were performed on entry, and
again at 6-12 month intervals. Disease free interval (DFI),
time to progression and survival were recorded.
Flow cytometry
Paraffin-embedded, formalin-fixed material was used
throughout. Blocks from the primary tumour (n= 125) or
from a skin metastasis (n= 11) were sectioned. Nuclear
suspensions for FCM analysis were prepared by the method
of Hedley et al., 1983, but with a slight modification of the
fluorochrome. A single 30pm section was dewaxed twice for
Omin in xylene, the rehydrated in reducing concentrations
of ethanol (100%, 95%, 70%, 50%) and washed in tris-
buffered saline (TBS), for 10min. The rehydrated sections
were incubated for 1 h in RNase (Sigma Co.) at a concen-
tration of lmgml-l and then exposed for 30min to 0.5%
pepsin adjusted by HCl to pH 1.5. Release of nuclei was
improved by vortex mixing or by gentle repeated aspiration.
Suspensions were centrifuged for 15min and pellets resus-
pended after filtration through nylon mesh in propidium
iodide staining solution (0.05mgml-1 in 1.12% sodium
citrate). Measurements were obtained from a cytofluoro-
graph model 4800A (Biophysics System Inc, Mahopac, New
Jersey, USA) with argon laster interfaced to a Hewlett-
Packard 9845A Desk Top Computer. Five thousand nuclei
were measured from each sample.
Analysis ofhistograms
Half peak coefficient of variability (CV) was evaluated for
each histogram and ranged from 2-10% (median 5%). For
the description of aneuploid peaks, DNA indices were used,
calculated as the ratio of the aneuploid peak channel to the
first peak, which was considered to be diploid or near
diploid and was present on each histogram (Coulson et al.,
1984). Diploid tumours were defined by DNA index 1.0-1.1,
'tetraploid' tumours by a diploid G2+M/tetraploid
GI .10% nuclei analysed, together with the presence of a
tetraploid G2+M peak. In multiploid tumours each peak
was defined by its own DNA index and the greatest one
used for the overall analysis. For calibration of the cyto-
fluorograph normal human peripheral blood lymphocytes,
fixed in 95% ethanol, and paraffin-embedded tonsils were
used. These gave comparable fluorescence for diploid
histograms.
Steroid hormone receptor assays
Tissue was stored in liquid nitrogen until the time of
receptor assay. The frozen sample was homogenised by
means of a Teflon capsule and tungsten ball which had been
pre-cooled with liquid nitrogen, and subjected to the action
of a dismembranator for 30sec. The resulting powder was
suspended in buffer (10mM Tris-HCI pH 7.4 with 1mM
EDTA, 0.5mM dithiothreitol and 30% v/v glycerol), and
centrifuged at 1,000g for 10min at 4°C to remove nuclei,
fat, and any debris.
For samples of weight greater than 200mg the dextran
coated charcoal assay was used to measure ER and PR:
values .5 fmolmg-1 cytosol protein were taken as positive
(Barnes et al., 1977). For smaller samples the method of
isoelectric focusing (IEF) was employed (Lloyd et al., 1982;
Harland et al., 1983). Any positive value with an appropriate
isoelectric point (pI) was taken to indicate a positive receptor
value. In both assays the total protein content was measured
by the BCA protein assay reagent (Pierce UK Ltd.,
Cambridge, UK).
Histopathology
Sections of tumour were processed routinely by a single
pathology laboratory. Tissue was fixed for up to 48h in
buffered formalin, and subsequently embedded in paraplast
medium on a Shandon tissue processor. Representative
blocks were sectioned at a thickness of 4,pm, mounted on
glass slides, stained with haematoxylin and eosin, cleared
and mounted with glass coverslips. Each section was
adjacent to the section that was taken for FCM analysis,
and was reviewed in a coded and randomised order by an
experienced single pathologist (LT). Sections in which the
area of tumour was <20% were discarded. The type of
tumour, the presence or absence of elastosis and invasion of
blood vessels and lymphatics was noted. Infiltrating duct
carcinomas were graded (Bloom & Richardson, 1957).
Statistical methods
All evaluations were made by the Chi-squared and Fisher's
exact tests when relating DNA ploidy to other variables.
Survival, time to progression, disease free interval and
survival from the start of treatment were calculated by the
life-table method. The log-rank test and Cox regression
analysis were used for comparisons between groups (Peto et
al., 1977).
Results
The major histopathological type, infiltrating duct carcinoma,
accounted for 123 of 136 (90%) tumours. There were 8 (6%)
cases of infiltrating lobular carcinoma, and 5 (4%) of
mucoid carcinoma. Lymphatic or vascular invasion was
apparent in 37 (27%) and the presence of elastosis, in 23
(17%). The frequency of DNA indices is shown (Figure 1).
Categorised into diploid (52 of 136, 38%) and total
aneuploid (84 of 136, 62%), there was no statistically signifi-
cant difference between these two groups with regard to
any of the other tumour or patient variables, including histo-
pathology, receptor status, response to endocrine therapy,
and survival. There was also no difference with regard to
DFI, survival from presentation, survival from the start of
treatment or time to progression (Figures 2, 3, 4 and 5).
Evaluations were repeated with the DNA histograms
grouped according to DNA index, to examine more closely
aneuploid sub-groups. Of the 136 tumours studied, 52 (40%)
had a DNA index of . 1.1 and were regarded as diploid or
near-diploid, 46 (34%) had DNA indices between 1.8 and
2.0: 19 (14%) were near-tetraploid with DNA index 1.8-1.9,
and 27 (20%), were tetraploid with an index of 2.0. The
remainder, 'other DNA-aneuploid', had DNA indices
between 1.2 and 1.7 or .2.1.
The highest proportion of oestrogen receptor positive
tumours was found in tumours with near-tetraploid DNA
indices between 1.8 and 1.9 (17 of 19, 90% ER positive) and
the tetraploid index of 2.0 (21 of 27, 81% ER positive)
(Table II).
The highest proportion of responders to endocrine therapy
was also found in these two subgroups (16 of 19, 84%, and
18 of 27, 67%, respectively. Table III). The range 1.8-2.0
was combined as the 'tetraploid' group, and compared with
the diploid and 'other DNA-aneuploid' groups. The
difference between the three groups for ER positivity was
highly significant (Chi-square=8.53, P<0.02). Of the
'tetraploid' tumours, 38 of 46 (83%) were ER positive,
compared with 35 of 52 (69%) of the diploid tumours, andFLOW CYTOMETRY ANALYSIS OF BREAST CANCER
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22 of 38 (57%) of the 'other DNA-aneuploid' tumours
(Table IV).
There was also a significant difference for response to
endocrine treatment: (Chi-square= 10.88, P<0.005). Of the
'tetraploid' tumours 34 of 46 (74%) responded, and 20 of
these 34 (59%) were complete or partial responses. Diploid
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Table II DNA index and receptor status
DNA index n= ER+ve PR+ve
.1.1 52 35 (69%) 28 (55%)
1.2-1.7 27 16 (59%) 14 (52%)
1.8-1.9 19 17 (90%) 11 (58%)
2.0 27 21 (81%) 16 (62%)
.2.1 11 6 (54%) 4 (36%)
P<0.02 P=0.51
Table III DNA index and response to endocrine therapy
DNA index n= CR+PR CR+PR+SD PD
. 1.1 52 16 (30%) 26 (50%) 26 (50%)
1.2-1.7 27 7 (26%) 12 (44%) 15 (54%)
1.8-1.9 19 9 (47%) 16 (85%) 3 (15%)
2.0 27 11 (41%) 18 (67%) 9 (23%)
.2.1 11 2 (18%) 3 (27%) 8 (67%)
P<0.04 P<0.01 P<0.01
Table IV DNA ploidy and receptor status
n= ER+ ve PR+ ve
Diploid 52 35 (69%) 28 (55%)
'Tetraploid"a 46 38 (83%) 27 (60%)
'Other DNA-aneuploid"b 38 22 (57%) 18 (47%)
Chi-square Chi-square
=8.53 = 1.62
P<0.02 P<0.40
aDNA indices 1.8-2.0 ('tetraploid'); bl.2-1.7 with
>2.1 ('other DNA-aneuploid').
Table V DNA ploidy and response to endocrine therapy
n= CR+PR CR+PR+SD PD
Diploid 52 16 (30%) 26 (50%) 26 (50%)
'Tetraploid"a 46 20 (43%) 34 (74%) 12 (26%)
'Other DNA-aneuploidb 38 9 (24%) 15 (39%) 23 (61%)
P<O.05 P<0.007 P<0.007
aDNA indices 1.8-2.0 ('tetraploid'); bl.2-1.7 with >2.1 ('other
DNA-aneuploid')
tumours had a 50% response rate, and 'other DNA-
aneuploid' tumours had a 39% response rate (Table V).
DNA ploidy had no influence on histopathological type
(Table VI). There was an insignificant trend for 'other DNA-
aneuploid' tumours to be of higher grade than diploid or
'tetraploid' tumours: 10 of 33 (30%) of 'other DNA-
aneuploid' tumours were grade III, compared with 13 of 81
(16%) of diploid or 'tetraploid' tumours. There was also an
Table VI DNA ploidy and histopathology type
Gradea
IDC I II III ILC Mucoid
Diploid 49 8 27 5 3 0
'Tetraploid' 40 9 24 7 3 3
'Other DNA-aneuploid' 34 4 19 10 2 2
IDC =infiltrating duct carcinoma, ILC=infiltrating lobular
carcinoma.
aGrade assessed on 113 of 123 infiltrating duct carcinomas.
P=NS for all variables.
insignificant trend for 'other DNA-aneuploid' tumours to
have a greater degree of nuclear pleomorphism and higher
number of mitoses than diploid and 'tetraploid' tumours
(Table VII). There was no difference in the incidence of
lymphatic or vascular invasion between the three groups, but
there was a trend, although still insignificant, for a higher
incidence of elastosis in 'tetraploid' tumours (10 of 41, 25%),
than in 'other DNA-aneuploid' tumours (5 of 33, 15%)
(Table VII).
Patients with diploid and 'tetraploid' tumours had a trend
for increased overall survival (P>0.06, Figure 6), a longer
time to progression on endocrine therapy (P<0.001, Figure
7) and a trend for increased survival from the start of
treatment when compared with patients with 'other DNA-
aneuploid' tumours (Figure 8). There was no significant
difference in the disease free interval between the three
groups - the increased survival and longer time to
progression for patients with diploid or 'tetraploid' tumours
related to the period after recurrence and institution of
therapy (Figure 9). When the diploid and 'tetraploid' groups
were combined there was a greater overall survival (P<0.03,
Figure 10), time to progression (P<0.01, Figure 11) and
trend for survival from the start of treatment (Figure 12).
But there remained no difference in the disease-free interval
between the groups (Figure 13).
100
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Figure 6 Survival from presentation -
'other DNA-aneuploid'.
diploid vs. 'tetraploid' vs.
Table VII DNA ploidy and histopathological variables
Nuclear grade Mitosis score
Elastosis Lymph./ Vasc.
I II III I II III present invasion present
Diploid 7 29 4 25 13 2 8 (18%) 14 (32%)
'Tetraploid' 4 28 9 23 14 4 10 (25%) 14 (34%)
'Other DNA-aneuploid' 3 21 9 13 15 5 5 (15%) 9 (30%)
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Discussion
Flow cytometric DNA analysis is rapid, objective,
reproducible and feasible for the routine examination not
only of fresh tissue but also of fixed paraffin embedded
samples (Hedley et al., 1983, 1985; Coon et al., 1986). The
use of standards is limited on paraffin-embedded material
because of the quality of fixation and possibly also on the
age of the blocks (Hedley et al., 1983). In this study normal
peripheral human lymphocytes and tonsil tissue blocks were
used to generate normal diploid DNA histogram patterns for
calibration and comparison for other histograms. The
advantages and drawbacks of paraffin-embedded tissue for
flow cytometry have been discussed fully elsewhere (Hedley
et al., 1985). Fresh tissue is usually not available when a
retrospective clinical study is being performed.
The cytofluorograph 4800A interfaced to the computer
with an established program allowed either 5,000 or 10,000
nuclei to be analysed. We did not find any difference for
interpretation between these two options, and from a
statistical point of view 5,000 nuclei were sufficient to plot
the distribution.
The results obtained with propidium iodide, a non-specific
nucleic acid stain, are comparable after ribonuclease pre-
treatment with the DNA-specific stain 4',6'-diamidino-2-
phenylindole (DAPI) (Taylor et al., 1980). In the initial
stages of this work we treated samples either before or after
pepsin digestion with RNase. Because the results were com-
parable, we preferred the technically simpler procedure of
RNase treatment before pepsin.
Many studies have attempted to relate DNA ploidy to
clinical and histological features, but the results have been
disappointing (Olszewski et al., 1981a; Cornelisse et al.,
1984; Horsfall et al., 1984; Coulson et al., 1984; Kute et al.,
1985; Stuart-Harris et al., 1985). Characterised convention-
ally into diploid and aneuploid, DNA ploidy analysis at
present neither adds to knowledge of tumour prognosis nor
influences therapy for an individual patient. Conventionally
the majority of breast carcinomas are described as aneuploid.
We found no difference between the diploid and total
aneuploid groups of tumours with respect to any other
variable, including histopathology, hormone receptor status,
response to endocrine therapy, and survival.
When the total aneuploid group was sub-divided into
'tetraploid' and 'other DNA-aneuploid' tumours, still no
clear-cut differences emerged with regard to histopathology.
There was a trend for diploid and 'tetraploid' tumours to be
of lower grade, lower mitosis score, and to have elastosis
present more frequently when compared with 'other DNA-
aneuploid' tumours, but this trend failed to achieve statistical
significance. These findings are in accord with those of
others: some studies found no association between histo-
logical differentiation and ploidy (Kute et al., 1985; Taylor
et al., 1983), whereas others found an insignificant trend for
diploid tumours to be of lower grade than the total group of
aneuploid tumours (Thorud et al., 1984; Moran et al., 1984;
Olszewski et al., 1981a, b).
Stuart-Harris et al. (1985) related response to treatment
with DNA ploidy in 42 endocrine treated evaluable patients,
and found no significant difference in response between the
diploid and aneuploid groups; there was no attempt to
subdivide the aneuploid group. In our study it was only
when the total aneuploid group was divided into 'tetraploid'
and 'other DNA-aneuploid' tumours that differences
emerged. The results indicate that 'tetraploid' or 'near-
tetraploid' tumours (DNA index 1.8-2.0) had a greater
probability of containing oestrogen receptors (85% were ER
positive), and of being responsive to endocrine therapy (74%
responded) than 'other DNA-aneuploid' tumours (57% were
ER positive. 39% responded). In addition patients with
'tetraploid' tumours survived longer and remained in
remission on endocrine therapy longer than those with 'other
DNA-aneuploid' tumours.
The definition of tetraploid peaks is an area of difficult
interpretation. Most authors do not define tetraploidy,
because they choose to distinguish only diploid from non-
diploid tumours. In one study by static cytometry, 50% (18
of 36) of good prognosis tumours were tetraploid, whereas
only 9% (10 of 42) of a poor prognosis group were
tetraploid (Auer et al., 1984). In the largest series published
on flow cytometry in breast cancer, the indidence of tetra-
ploid tumours reported is significantly lower than ours
(Ewers et al., 1984). The probable explanation lies in inter-
pretation. In that study, tetraploid was defined as a diploid
G2+M/tetraploid GI peak representing _20% of analysed
nuclei, together with the presence of a tetraploid G2+M
peak. In our study we included as 'tetraploid' histograms
with diploid G2 + M/tetraploid GI peaks >10% of analysed
nuclei, together with the presence of a tetraploid G2+M
peak. We widened the criteria because it is impossible to
distinguish diploid from tetraploid tumours by DNA histo-
gram analysis alone, and doubt has been expressed with
regard to the validity of using the figure of 20% as the
threshold (Ewers et al., 1984). We used a cut-off point of
10%, because that was the threshold at which tetraploid
G2+M peaks were apparent, at a position corresponding to
the approximate position of DNA index of 4.0. We do not
suppose that clumping of nuclei was significant in our study,
because there was no significant occurrence of sextaploid
indices (triplets), which should be present also if doublets
have been produced by clumping. Internationally accepted
nomenclature for flow cytometry does not include a
definition of tetraploid (Hiddemann et al., 1984). We
included tumours with histograms of DNA index 1.8-2.0, as
'tetraploid' in order to accommodate the coefficients of
variation (.10%) in DNA index which can occur with the
use of paraffin-embedded tissue (Hedley et al., 1983, 1985).
Furthermore we evaluated them together because hypotheti-
cally they may be generated by similar mechanisms (Baildam
et al., 1987).
Auer ettil. (1984) used the technique of static cytometry in
breast cancer, and in that series the majority of patients who
survived 15 years or more from diagnosis had diploid or
tetraploid tumours. Most who died within 2 years had
tumours that were hyperdiploid, hypertetraploid, or hypo-
diploid. This was confirmed by Coulson et al. (1984) with
flow cytometry on fresh tissue: 22 of 24 (92%) patients who
died during the 36 month follow up period had tumours
classified into one of these three 'other DNA-aneuploid'
groups.
The method of analysis on paraffin-embedded material
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therefore any such tumours are included in the near-diploid
group (Hedley et al., 1984). Hypodiploid tumours account
for 8% of breast cancers, and they have both poor prognosis
and low receptor positivity (Coulson et al., 1984). This may
account for the lower response rate and lower number of
receptor positive tumours in our diploid group compared
with the 'tetraploid', although both are greater than in the
'other DNA-aneuploid' group.
There was no difference in disease free interval between
any of the groups studied. Patients with diploid or
'tetraploid' tumours had longer overall survival from first
presentation, longer survival from the start of treatment and
longer time to progression than those with 'other DNA
aneuploid' tumours. These findings were consistent with the
incidence of oestrogen receptor positivity and the incidence
of response to endocrine therapy in the diploid and 'tetra-
ploid' tumours. Patients with advance disease who have ER
positive tumours or who respond to endocrine treatment
survive 1-3 years longer than those with either ER negative
tumours or those which are non-responders. The longer
period of survival is often of high quality (Howell et al.,
1984).
In conclusion we have found that in patients with
advanced disease, the conventional division of tumours into
diploid and total aneuploid groups may mask important
features of aneuploid sub-groups. We suggest that 'tetra-
ploid' or 'near-tetraploid' human mammary tumours may
comprise a distinct group of endocrine responsive tumours
within the overall group of aneuploid tumours.
A.D.B. was in receipt of a grant from the Cancer Research
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